01—Abstract
Summary
Summary of the 10-Q filed February 4, 2026. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. reported solid financial results for the quarter ending December 31, 2025, demonstrating robust revenue growth driven by both its U.S. and International Healthcare Solutions segments.
The company saw a significant increase in gross profit, largely attributed to the acquisition of RCA and favorable LIFO credit adjustments, while managing operating expenses effectively despite integration costs from recent acquisitions. Despite a notable increase in interest expense due to recent debt financings for acquisitions, Cencora maintained profitability, with net income attributable to Cencora, Inc. rising to $559.6 milliona.
The company also provided strong forward-looking indications with the recent acquisition of OneOncology and an increased revolving credit facility, positioning it for continued growth and operational expansion. However, investors should remain aware of the ongoing opioid litigation accrual and other contingent liabilities, which represent a significant long-term financial commitment.
02—Key points
Key Highlights
- Revenue increased by 5.5% to $85.9 billion year-over-year, driven by growth in both U.S. and International Healthcare Solutions segments, including $1 billion in sales from GLP-1 products.
- Gross profit saw a substantial increase of 20.1% to $3.1 billion, boosted by the RCA acquisition, increased sales, and a $70.2 million rise in LIFO credit.
- Net income attributable to Cencora, Inc. grew to $559.6 million ($2.87 diluted EPS), up from $488.6 million ($2.50 diluted EPS) in the prior year period.
- The company recorded a goodwill impairment of $165.7 million related to its U.S. Consulting Services business classified as held for sale.
- Total debt increased to $7.9 billion, primarily due to new debt financing for acquisitions, with a significant portion being variable-rate debt.
- Cencora completed a major acquisition of OneOncology in early February 2026 for approximately $4.6 billion, funded by new debt financing.
- The company maintains a substantial accrued litigation liability of $4.3 billion for opioid-related matters, with estimated payments of $426.2 million expected within the next year.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2026, Cencora, Inc. kept $0.01.
- Revenue$85.93B100.0%
- Cost of revenue−$82.86B96.4%
- Gross profit$3.07B3.6%
- Operating costs−$2.31B2.7%
- Operating income$760.4M0.9%
- Interest, other & tax−$200.8M0.2%
- Net income$559.6M0.7%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2026filed February 4, 2026Financial Statements
Q1 FY2026 against Q1 FY2025
| Line item | Q1 FY2026Q1 FY2025 | Change |
|---|---|---|
| Revenue | $85.93B$81.49B | +5.5% |
| Cost of Revenue | $82.86B$78.93B | +5.0% |
| Gross Profit | $3.07B$2.56B | +20.1% |
| SG&A Expenses | $1.80B$1.47B | +22.0% |
| Operating Expenses | $1.93B$1.59B | +21.7% |
| Operating Income | $760.45M$706.25M | +7.7% |
| Net Income | $559.65M$488.60M | +14.5% |
| EPS (Basic) | $2.88$2.52 | +14.3% |
| EPS (Diluted) | $2.87$2.50 | +14.8% |
| Shares Outstanding (Basic) | 194.22M193.76M | +0.2% |
| Shares Outstanding (Diluted) | 195.32M195.19M | +0.1% |
05—Questions
Frequently Asked Questions
What was the primary driver of Cencora's revenue growth this quarter?
Cencora's revenue grew by 5.5% to $85.9 billion, primarily driven by increased sales in both its U.S. Healthcare Solutions and International Healthcare Solutions segments. This growth was bolstered by strong unit volume increases, specialty product sales, and notably, $1.0 billion in sales from GLP-1 class products.
How has the RCA acquisition impacted the company's financial performance?
The acquisition of RCA, completed in January 2025, had a positive impact on Cencora's financial performance. It contributed to a significant increase in gross profit for the U.S. Healthcare Solutions segment and drove higher operating income for the segment. However, it also contributed to increased operating expenses and distribution, selling, and administrative costs.
What is the company's current financial position regarding debt and liquidity?
Cencora's total debt increased to $7.9 billion as of December 31, 2025, largely due to financing new acquisitions. The company has access to substantial liquidity through its multi-currency revolving credit facility, which was increased to $5.5 billion in January 2026, and other credit facilities. Despite increased interest expenses, the company's operating cash flows and available credit lines are expected to be sufficient to meet its ongoing obligations, including significant opioid litigation payments.
What is the status and potential impact of the opioid litigation accrual?
Cencora has an accrued litigation liability of $4.3 billion for opioid-related matters, which is expected to be paid over 13 years. Of this amount, approximately $426.2 million is expected to be paid within the next year. While the company has accrued its estimated liability, it notes that the ultimate loss may differ materially from the amount accrued, and the ongoing litigation remains a significant contingency.
06—Continue